Sanofi SNY announced that the FDA has accepted the supplemental biologics license application (sBLA), seeking expanded use of its multiple myeloma drug, Sarclisa (isatuximab). The sBLA seeks approval ...
Source LinkSanofi SNY announced that the FDA has accepted the supplemental biologics license application (sBLA), seeking expanded use of its multiple myeloma drug, Sarclisa (isatuximab). The sBLA seeks approval ...
Source Link
Comments